About AgonOx
The immune system is the body’s first line of defense against cancer. Many times each day normal cells lose control and become cancerous – but these cells are quickly attacked and eliminated by the immune system. Sometimes, however, groups of abnormal cells begin to grow, creating tumors.
AgonOx is developing OX40 agonists and other immune system activators for use in cancer therapy. Lead agents include a soluble form of OX40 Ligand (above left) that complexes two OX40L trimers, and a humanized anti-human OX40 monoclonal antibody (above right). Both are designed to bind OX40 and generate the same activation signal produced by the binding of OX40L to OX40 (central figure) on T cells in the body. Research in the field of T-cell modulation conducted worldwide with OX40 and other agents has demonstrated that the use of T-cell modulating therapies in combination with specific anti-tumor therapies has the potential for yielding dramatic benefits for patients with cancer. AgonOx is focused on the development of immune system modulators in combination with other promising therapies.
